Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

BACKGROUND: Biologics are effective for the treatment of psoriasis. However, treatment outcomes may differ among biologic‐naive patients and those switched from previous biological therapies. OBJECTIVES: The study's objective was to investigate efficacy and safety of ixekizumab, a high‐affinity...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, A.B., Lacour, J.‐P., Korman, N., Wilhelm, S., Dutronc, Y., Schacht, A., Erickson, J., Zhang, L., Mallbris, L., Gerdes, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412924/
https://www.ncbi.nlm.nih.gov/pubmed/27696577
http://dx.doi.org/10.1111/jdv.13990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412924/
https://www.ncbi.nlm.nih.gov/pubmed/27696577
http://dx.doi.org/10.1111/jdv.13990

Ejemplares similares